Finance

Lists
ZYDUSLIFE:NSE
Zydus Lifesciences Ltd
1 123,00 INR
-1,51%
(-17,20) 1D
16-окт., 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for ZYDUSLIFE...
Open
1 140,10 INR
High
1 146,50 INR
Low
1 123,00 INR
Mkt. cap
1,12 трлн
Avg. vol.
1,42 млн
Volume
1,60 млн
Dividend
0,09%
Quarterly dividend
0,25 INR
Ex-dividend date
2026-ж., 24-июл.
P/E ratio
25,03
52-wk high
1 232,10 INR
52-wk low
835,50 INR
EPS
44,87 INR
No. of employees
30 миң
Open
1 140,10 INR
High
1 146,50 INR
Low
1 123,00 INR
Mkt. cap
1,12 трлн
Avg. vol.
1,42 млн
Volume
1,60 млн
Dividend
0,09%
Quarterly dividend
0,25 INR
Ex-dividend date
2026-ж., 24-июл.
P/E ratio
25,03
52-wk high
1 232,10 INR
52-wk low
835,50 INR
EPS
44,87 INR
No. of employees
30 миң
News stories
From web sources and news partners
Profile
Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited, is an Indian multinational pharmaceutical company headquartered in Ahmedabad. Primarily engaged in the manufacturing of generic drugs, the company ranked 100th in the Fortune India 500 list in 2020. Wikipedia
About Zydus Lifesciences Ltd
CEO-
Employees30 миң
Founded1952
Headquarters-
SectorPharmaceutical industry
Last report
2026-ж., 11-авг.
Fiscal period
Q1 2027
9,48 INR / 11,15 INR
-14,98%miss
Revenue / Est. (INR)
80,17 млд / 76,87 млд
+4,30%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
61,23 млд
68,64 млд
75,87 млд
80,17 млд
Cost of goods sold
16,90 млд
18,36 млд
22,07 млд
22,40 млд
Cost of revenue
16,90 млд
18,36 млд
22,07 млд
22,40 млд
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10,34 млд
11,40 млд
32,92 млд
13,68 млд
Operating expense
31,33 млд
37,36 млд
39,40 млд
44,59 млд
Total operating expenses
48,23 млд
55,72 млд
61,48 млд
66,99 млд
Operating income
13,00 млд
12,92 млд
14,39 млд
13,18 млд
Other non operating income
1,09 млд
1,11 млд
-3,70 млд
1,06 млд
EBT including unusual items
16,93 млд
14,11 млд
16,59 млд
13,44 млд
EBT excluding unusual items
17,27 млд
14,96 млд
20,88 млд
13,63 млд
Income tax expense
4,54 млд
3,88 млд
3,18 млд
3,54 млд
Effective tax rate
26,82%
27,52%
19,19%
26,35%
Other operating expenses
17,97 млд
22,36 млд
1,28 млд
25,36 млд
Net income
12,59 млд
10,42 млд
12,72 млд
9,40 млд
Net profit margin
20,55%
15,18%
16,77%
11,72%
Earnings per share
12,76
10,96
15,84
9,48
Interest and investment income
-
-
4,24 млд
-
Interest expense
-1,01 млд
-1,30 млд
-491,00 млн
-1,56 млд
Net interest expenses
-1,01 млд
-1,30 млд
3,75 млд
-1,56 млд
Depreciation and amortization charges
3,02 млд
3,60 млд
5,08 млд
5,55 млд
EBITDA
15,70 млд
15,10 млд
17,74 млд
16,53 млд
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google колдонмолору